Starting With The End In Mind: How Agile CDMO Partnerships Keep Complex Biologics Programs Moving From Development Through GMP

By Pablo Gutiérrez Gómez, CEO & Carmen Martínez, COO — 53Biologics

As biologics pipelines grow more complex, success depends on more than advancing from one milestone to the next. Novel modalities such as multispecifics, recombinant proteins, and viral vectors introduce challenges that make early development decisions critical to long-term manufacturing outcomes. An integrated approach that considers GMP requirements, scalability, analytical development, and technology transfer from the outset can help reduce costly delays and prevent redevelopment later in the program lifecycle.

Many organizations still rely on multiple vendors across development, analytical testing, manufacturing, and fill-finish, creating handoffs where scientific knowledge can be lost and momentum slowed. By maintaining continuity of teams and scientific understanding, developers can better manage evolving data, regulatory expectations, and process complexity. Agile CDMO partnerships enable closer collaboration, faster adaptation to change, and a stronger foundation for successful scale-up.

For organizations developing complex biologics, preserving knowledge and planning with the end goal in mind can be the difference between a smooth path to GMP and months of avoidable rework.